Steve Shuttleworth

Dr. Steve Shuttleworth is a Venture Partner at Samsara BioCapital, having joined in 2019. From 2008-2019 he was CSO at Karus Therapeutics, and from 2017-2019 joint COO/CSO. He was the founding scientist of Karus’s PI3K and HDAC6 programs and designed and directed the research and preclinical development of the two small molecule cancer therapeutics, KA2237 and KA2507, from concept to Phase I clinical trials. Previously, Steve held R&D leadership positions in UK and North American biotech, working in several disease areas across multiple therapeutic targets, notably at Chiroscience, BiochemPharma, Tularik, CRUK and Piramed. At Piramed, he directed the PI3K research programs, designing and leading the preclinical development of Pictilisib, partnered with Genentech, and subsequently taken into Phase II by Roche, who acquired Piramed for $160M in 2008. Steve obtained his BSc (Hons) and PhD in Chemistry from the University of Liverpool, and in 2007 he was appointed a Fellow of the Royal Society of Chemistry​.